This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-06. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
=== Mechanism of action === Dasiglucagon operates through the same mechanism as endogenous glucagon, acting as an agonist at glucagon receptors expressed throughout the body, which are G-coupled receptors. Binding to liver glucagon receptors, dasiglucagon activates Gsα and Gq, resulting in the activation of adenylate cyclase. This, in turn, increases intracellular cyclic AMP levels, stimulating glycogenolysis and gluconeogenesis in the liver. As glucose is primarily released from liver glycogen stores, the presence of glycogen stores in the liver is essential for dasiglucagon to exert its antihypoglycemic effects
=== Medical === Some carbamate esters have use as muscle relaxants, including Emylcamate, Phenprobamate, Styramate and other members of ATC code M03BA. These bind to the barbiturate site of the GABAA receptor.
In October 2013, Basilea received marketing authorisation in twelve European countries, including Germany, for the distribution of the broad-spectrum antibiotic Ceftobiprole for the treatment of bacterial lung infections; in the following two years, the drug was gradually approved in other European countries and non-EU countries. Ceftobiprole has been approved in 32 countries and has been marketed in 21 countries since the end of 2023. In 2020, Basilea sold the group headquarters in Basel to the pension fund of the Swiss bank UBS by way of a sale-leaseback and moved to its new headquarters in Allschwil in mid-2022. The gross proceeds from the sale amounted to around CHF 19 million before fees and transaction costs. In 2021, Basilea Pharmaceutica China Ltd. was sold to the US company PHT International. Basilea was previously active in oncological research, but withdrew from it at the beginning of 2022 and has since been focusing purely on anti-infectives. In 2023, Basilea acquired the rights to the antifungal drug Fosmanogepix from Pfizer. By the end of 2023, Isavuconazole was commercialised in more than 70 countries, including the United States, most EU countries, China and Japan. Isavuconazole's total global sales in the twelve-month period between October 2022 and September 2023 amounted to CHF 406 million. This corresponds to growth of 22 per cent compared to the previous year.
== Composition == Whole leaf protein concentrate is a dark green substance with a texture similar to cheese. Approximately 60% of this is water, while the remaining dry matter is 9-11% nitrogen, 20-25% lipid, 5-10% starch and a variable amount of ash. It is a mixture of many individual proteins. Its flavour has been compared to spinach or tea. Because the colour and taste may make it unpalatable for humans, LPC can instead be separated into green and white fractions. The green fraction has proteins mainly originating from the chloroplasts, while the white fraction has proteins mainly originating from the cytoplasm.
Sources: en.wikipedia.org
According to the New York Times, the super PACs criticize politicians who are "insufficiently supportive of the push into artificial intelligence" ahead of the 2026 midterm elections. In February 2026 the nonprofit organization Public First Action, which received a $20 million donation from Anthropic, announced plans to support political candidates that support regulation of AI. In December 2025, Trump signed Executive Order 14365, "Ensuring a National Policy Framework for Artificial Intelligence", which seeks to preempt state regulation. The White House published "A National Legislative Policy Framework for Artificial Intelligence: Legislative Recommendations" in March 2026, a set of recommendations to Congress for federal legislation. The recommendations ask Congress to act in various ways to implement the Trump administration's strategy for artificial intelligence policy. Export controls on AI chips and semiconductors are imposed by the United States, restricting the export of technology and equipment related to artificial intelligence to other countries, primarily targeting China. In January 2026, BIS formalized a flexible license review policy for these transactions. This has happened in the context of a broader trade war. In June 2026, the U.S. Department of Commerce expanded export controls beyond AI hardware by requiring licenses for certain frontier artificial intelligence models from Anthropic, while authorizing release to specified trusted partners.
== Formats and the submission process == Since detailed proteomics data currently cannot be curated from the existing literature, the source of PRIDE data is solely submissions by academic researchers. PRIDE is a standards-compliant public repository, meaning that its own XML-based data exchange format for submissions, PRIDE XML, was built around the Proteomics Standards Initiative mzData standard for mass spectrometry. Recently, PRIDE has been adapted to work with the modern mzML and mzIdentML standards of the Proteomics Standards Initiative. An additional format, dubbed mzTab, can be used as a simplified way to submit quantitative proteomics data. As there are many types of different mass spectrometry instruments and software formats are currently on the market, wet-lab scientists without a strong bioinformatics background or informatics support were having problems converting their data to PRIDE XML. The development of PRIDE Converter helped to tackle this situation. PRIDE Converter is a tool, written in the Java programming language, that converts 15 different input mass spectrometry data formats into PRIDE XML via a wizard-like graphical user interface. It is freely available and is open source under the permissive Apache License. A new version of PRIDE Converter was released in 2012 as PRIDE Converter 2. This new version constituted a complete rewrite, focused on easy adaptability to different (and evolving) data sources.
Truck terminals in proximity to industrial clusters, machinery and manufacturing units, agro-processing zones, and integrated cold-chain storage facilities will be planned to build the export-ready and quick logistics infrastructure. The HHBTMSM Expressway will have a separate provision for the optical fiber connectivity and gas pipelines, turning the greenfield expressway into a 'digital-ready' utility corridor.
=== India === The Indian Armed Forces issues a host of rations including the One Man Combo Pack Ration, Mini Combo Pack, Survival Ration, and Main Battle Tank Rations. The shelf-life of the ration is 12 months. India has adopted retort processing technology for combat rations. The rations use pre-cooked thermostabilized entrees in a plastic-foil laminate retort pouch. The ration does not require cooking and the contents may be eaten cold, though warming is preferred. An entire day's worth of food, plus accessory items, is packed inside a heavy-duty olive green plastic bag with pasted on label. The menu consists of several different Vegetarian and Non-Vegetarian products that cater to Indian tastes, such as sooji halwa, chapatis, tea mix, chicken biryani, chicken curry, Kebab, Tandoori, Panneer, Organic Egg, Butter naan, mutton biryani, Mutton curry, Vegetable biryani, rajma curry, dal fry, jeera rice, Dal makhani, vegetable pulav and mixed vegetable curry, alongside pickled hot seasoning, in small plastic pouches. The One Man Combo Pack consists of early morning tea, breakfast, mid morning tea, lunch, evening tea, and dinner. The menus feature both dehydrated and ready-to-eat products, and include a folding stove and hexamine fuel tablets. The ration weighs 880 grams and provides 4,100 kcal (17,000 kJ). The Mini Combo Pack is a simplified version of the One Man Combo Pack, weighing 400 g and providing 1,520 kcal (6,400 kJ). The Survival Ration consists of a soft bar and chikki.
Health can play a central role in how people live their lives, reflecting the overall condition in which an organism functions properly, both physically and mentally. Good physical health is associated with high energy and the ability to perform everyday activities. Physical illnesses and disabilities can negatively impact well-being by causing pain, limiting mobility, and reducing the capacity to engage in enjoyable or necessary activities. Good mental health is a state of internal equilibrium in which mental capacities function as they should. Mental disorders are associated with some form of psychological impairment: they typically disrupt the equilibrium by causing distress and may limit the activities a person can engage in. Discrimination can amplify the negative effects of socially stigmatized illnesses and disabilities. Despite its general impact, health does not fully determine happiness, and some individuals affected by severe illnesses and disabilities report high levels of subjective well-being. The availability of healthcare services can mitigate negative effects by providing treatments to restore health or manage and alleviate symptoms. Similarly, adopting a healthy lifestyle, like regular physical activity and a balanced diet, is associated with long-term benefits to well-being.
Sources: en.wikipedia.org
Scott at the University of Chicago tried aqueous pancreatic extracts and noted "a slight diminution of glycosuria", but was unable to convince his director of his work's value; it was shut down. Israel Kleiner demonstrated similar effects at Rockefeller University in 1915, but World War I interrupted his work and he did not return to it. In 1916, Nicolae Paulescu developed an aqueous pancreatic extract which, when injected into a diabetic dog, had a normalizing effect on blood sugar levels. He had to interrupt his experiments because of World War I, and in 1921 he wrote four papers about his work carried out in Bucharest and his tests on a diabetic dog. Later that year, he published "Research on the Role of the Pancreas in Food Assimilation". The name "insulin" was coined by Edward Albert Sharpey-Schafer in 1916 for a hypothetical molecule produced by pancreatic islets of Langerhans (Latin insula for islet or island) that controls glucose metabolism. Unbeknown to Sharpey-Schafer, Jean de Meyer had introduced the very similar word "insuline" in 1909 for the same molecule.
=== Phase 3 === Clomipramine/sildenafil (CDFR-0812) – combination of clomipramine (tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions) and sildenafil (phosphodiesterase PDE5 inhibitor) – premature ejaculation [5] Gepirone (Ariza; BMY-13805-1; BMY-13805; Exxua; Gepirone ER; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist, other actions – decreased libido [6] Nitroglycerin gel (Eroxon; glyceryl trinitrate topical gel; MED-2001; MED-2003; MED-2004; MED-2005; MED-3000; MED2002) – guanylate cyclase stimulant, nitric oxide donor, nitric oxide stimulant – erectile dysfunction [7] Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – decreased libido [8] Sacubitril/valsartan (AHU-377/valsartan; Enrest; Enresuto; Entresto; Entresto Sprinkle; LCZ-696; LCZ-696A; Neparvis; valsartan/AHU-377; valsartan/sacubitril) – combination of sacubitril (neprilysin inhibitor) and valsartan (angiotensin II receptor type 1 (AT1) antagonist) – erectile dysfunction [9]
=== Malay === Malay, just like Indonesian, is an agglutinative language (at least in the formal language) and it belongs to the Austronesian language family. The longest word in Malay is mempertanggungjawabkan, which is 22 letters long, meaning "to give responsibility to" in English.
Humans have domesticated plants and animals since around 12,000 BCE, using selective breeding or artificial selection (as contrasted with natural selection). The process of selective breeding, in which organisms with desired traits (and thus with the desired genes) are used to breed the next generation and organisms lacking the trait are not bred, is a precursor to the modern concept of genetic modification. Various advancements in genetics allowed humans to directly alter the DNA and therefore genes of organisms. In 1972, Paul Berg created the first recombinant DNA molecule when he combined DNA from a monkey virus with that of the lambda virus. Herbert Boyer and Stanley Cohen made the first genetically modified organism in 1973. They took a gene from a bacterium that provided resistance to the antibiotic kanamycin, inserted it into a plasmid and then induced other bacteria to incorporate the plasmid. The bacteria that had successfully incorporated the plasmid was then able to survive in the presence of kanamycin. Boyer and Cohen expressed other genes in bacteria. This included genes from the toad Xenopus laevis in 1974, creating the first GMO expressing a gene from an organism of a different kingdom.
Spinal cord stimulation is a form of invasive neuromodulation therapy in common use since the 1980s. Its principal use is as a reversible, non-pharmacological therapy for chronic pain management that delivers mild electrical pulses to the spinal cord. In patients who experience pain reduction of 50 percent or more during a temporary trial, a permanent implant may be offered in which, as with a cardiac pacemaker, an implantable pulse generator about the size of a stopwatch is placed under the skin on the trunk. It delivers mild impulses along slender electrical leads leading to small electrical contacts, about the size of a grain of rice, at the area of the spine to be stimulated. Stimulation is typically in the 20–200 Hz range, though a novel class of stimulation parameters are now emerging that employ a 10 kHz stimulation train as well as 500 Hz "burst stimulation". Kilohertz stimulation trains have been applied to both the spinal cord proper as well as the dorsal root ganglion in humans. All forms of spinal cord stimulation have demonstrated varying degrees of efficacy in treating a variety of pharmacoresistant neuropathic or mixed (neuropathic and nociceptive) pain syndromes, such as post-laminectomy syndrome, low back pain, complex regional pain syndrome, peripheral neuropathy, peripheral vascular disease, and angina. The general process for spinal cord stimulation involves a temporary trailing of appropriate patients with an external pulse generator attached to epidural electrodes located in the lower thoracic spinal cord.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.